cMD was found to be associated with PET tau in vulnerable to AD pathology regions and predict hippocampal atrophy rate and cognitive decline while cortical microstructure changes in the frontal and parietal areas appeared to be sensitive biomarkers for microstructural alterations in FTLD subtypes [57–59]. The gene discussed is MAPT; the disease is Alzheimer disease.